Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
Blood Cancer J. 2022 Apr 11;12(4):57. doi: 10.1038/s41408-022-00664-y.
Blood Cancer J. 2022.
PMID: 35410412
Free PMC article.
No abstract available.
Integrative Analyses Reveal the Anticancer Mechanisms and Sensitivity Markers of the Next-Generation Hypomethylating Agent NTX-301.
Lim B, Yoo D, Chun Y, Go A, Kim JY, Lee HY, Boohaker RJ, Cho KJ, Ahn S, Lee JS, Jung D, Choi G.
Lim B, et al. Among authors: yoo d.
Cancers (Basel). 2023 Mar 13;15(6):1737. doi: 10.3390/cancers15061737.
Cancers (Basel). 2023.
PMID: 36980623
Free PMC article.
Item in Clipboard
Cite
Cite